MediciNova (MNOV) Competitors $1.34 -0.07 (-4.96%) Closing price 04/3/2025 04:00 PM EasternExtended Trading$1.51 +0.17 (+12.69%) As of 08:44 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock MNOV vs. GLUE, TSHA, ESPR, TKNO, ATAI, ATYR, CADL, CMPS, CMPX, and PRMEShould you be buying MediciNova stock or one of its competitors? The main competitors of MediciNova include Monte Rosa Therapeutics (GLUE), Taysha Gene Therapies (TSHA), Esperion Therapeutics (ESPR), Alpha Teknova (TKNO), Atai Life Sciences (ATAI), Atyr PHARMA (ATYR), Candel Therapeutics (CADL), COMPASS Pathways (CMPS), Compass Therapeutics (CMPX), and Prime Medicine (PRME). These companies are all part of the "pharmaceutical products" industry. MediciNova vs. Monte Rosa Therapeutics Taysha Gene Therapies Esperion Therapeutics Alpha Teknova Atai Life Sciences Atyr PHARMA Candel Therapeutics COMPASS Pathways Compass Therapeutics Prime Medicine Monte Rosa Therapeutics (NASDAQ:GLUE) and MediciNova (NASDAQ:MNOV) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their community ranking, media sentiment, profitability, dividends, risk, earnings, institutional ownership, analyst recommendations and valuation. Does the media favor GLUE or MNOV? In the previous week, Monte Rosa Therapeutics had 1 more articles in the media than MediciNova. MarketBeat recorded 2 mentions for Monte Rosa Therapeutics and 1 mentions for MediciNova. Monte Rosa Therapeutics' average media sentiment score of 1.56 beat MediciNova's score of 0.59 indicating that Monte Rosa Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Monte Rosa Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive MediciNova 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts rate GLUE or MNOV? Monte Rosa Therapeutics presently has a consensus price target of $15.50, suggesting a potential upside of 298.46%. MediciNova has a consensus price target of $9.00, suggesting a potential upside of 571.64%. Given MediciNova's stronger consensus rating and higher possible upside, analysts plainly believe MediciNova is more favorable than Monte Rosa Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Monte Rosa Therapeutics 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.75MediciNova 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the MarketBeat Community prefer GLUE or MNOV? MediciNova received 196 more outperform votes than Monte Rosa Therapeutics when rated by MarketBeat users. However, 48.48% of users gave Monte Rosa Therapeutics an outperform vote while only 47.53% of users gave MediciNova an outperform vote. CompanyUnderperformOutperformMonte Rosa TherapeuticsOutperform Votes1648.48% Underperform Votes1751.52% MediciNovaOutperform Votes21247.53% Underperform Votes23452.47% Which has better earnings & valuation, GLUE or MNOV? MediciNova has lower revenue, but higher earnings than Monte Rosa Therapeutics. MediciNova is trading at a lower price-to-earnings ratio than Monte Rosa Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMonte Rosa Therapeutics$75.62M3.16-$135.35M-$1.02-3.81MediciNova$1M65.72-$8.56M-$0.23-5.83 Is GLUE or MNOV more profitable? MediciNova's return on equity of -19.66% beat Monte Rosa Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Monte Rosa TherapeuticsN/A -62.68% -38.83% MediciNova N/A -19.66%-18.63% Which has more risk and volatility, GLUE or MNOV? Monte Rosa Therapeutics has a beta of 1.5, meaning that its share price is 50% more volatile than the S&P 500. Comparatively, MediciNova has a beta of 0.73, meaning that its share price is 27% less volatile than the S&P 500. Do insiders and institutionals hold more shares of GLUE or MNOV? 80.0% of Monte Rosa Therapeutics shares are held by institutional investors. Comparatively, 9.9% of MediciNova shares are held by institutional investors. 6.5% of Monte Rosa Therapeutics shares are held by company insiders. Comparatively, 14.9% of MediciNova shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. SummaryMediciNova beats Monte Rosa Therapeutics on 9 of the 17 factors compared between the two stocks. Remove Ads Get MediciNova News Delivered to You Automatically Sign up to receive the latest news and ratings for MNOV and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MNOV vs. The Competition Export to ExcelMetricMediciNovaPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$65.72M$6.72B$5.53B$7.50BDividend YieldN/A2.85%4.87%4.05%P/E Ratio-5.836.9923.1218.08Price / Sales65.72198.60360.0289.38Price / CashN/A65.6738.1634.64Price / Book1.255.926.473.99Net Income-$8.56M$142.37M$3.21B$247.18M7 Day Performance-7.59%-7.24%-4.97%-4.25%1 Month Performance-14.65%-10.45%-0.14%-6.87%1 Year Performance-8.22%-14.58%6.19%-3.73% MediciNova Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MNOVMediciNova1.6383 of 5 stars$1.34-5.0%$9.00+571.6%-11.8%$65.72M$1M-5.8310Gap DownGLUEMonte Rosa Therapeutics3.0054 of 5 stars$4.64-9.0%$15.50+234.1%-43.9%$285.41M$75.62M-2.5490Short Interest ↓TSHATaysha Gene Therapies1.9065 of 5 stars$1.39-28.0%$6.63+376.6%-53.7%$284.95M$8.33M2.21180Gap DownHigh Trading VolumeESPREsperion Therapeutics3.695 of 5 stars$1.44-4.0%$6.75+368.8%-58.7%$284.90M$332.31M-2.25200TKNOAlpha Teknova1.1542 of 5 stars$5.19-0.4%$8.50+63.8%+94.8%$277.34M$37.75M-7.01240Positive NewsGap DownHigh Trading VolumeATAIAtai Life Sciences3.49 of 5 stars$1.36-7.5%$9.00+561.8%-45.0%$269.70M$308,000.00-1.6880Positive NewsGap DownATYRAtyr PHARMA2.5362 of 5 stars$3.02-3.5%$18.60+515.9%N/A$268.35M$235,000.00-3.2153Gap DownCADLCandel Therapeutics2.2459 of 5 stars$5.65-5.0%$21.00+271.7%+212.5%$266.88M$120,000.00-3.2760Gap DownCMPSCOMPASS Pathways3.24 of 5 stars$2.86-2.7%$21.83+663.4%-70.8%$265.05MN/A-1.30120Gap DownCMPXCompass Therapeutics3.0235 of 5 stars$1.90-4.5%$11.38+498.7%-13.2%$262.74M$850,000.00-5.1320Analyst ForecastOptions VolumeAnalyst RevisionNews CoverageGap UpHigh Trading VolumePRMEPrime Medicine2.3033 of 5 stars$1.99flat$13.38+572.1%-72.2%$261.01M$2.98M-0.97234Gap DownHigh Trading Volume Remove Ads Related Companies and Tools Related Companies GLUE Competitors TSHA Competitors ESPR Competitors TKNO Competitors ATAI Competitors ATYR Competitors CADL Competitors CMPS Competitors CMPX Competitors PRME Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MNOV) was last updated on 4/4/2025 by MarketBeat.com Staff From Our PartnersTrump Allies Confirm Exec Order 14024 Triggers Dollar CollapseExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | SponsoredTrump Orders 'National Digital Asset Stockpile'‘Digital Asset Reserve’ for THIS Coin??? Get all the details before this story gains even more tractionCrypto 101 Media | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredTrump’s Secret WeaponPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredYour Retirement Is Caught in the CrossfireWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredCaught on Camera: Elon Musk’s “Area 51”You won’t believe what tech legend Jeff Brown found in what he calls Elon Musk’s “Area 51.” (Click here to see...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MediciNova, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share MediciNova With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy MNOV Stock Free MNOV Stock Alerts